This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SOUTH SAN FRANCISCO, Calif.,
July 2, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced that the company will present at the 2013 JMP Securities Healthcare Conference on
July 10 in New York City. KaloBios President and Chief Executive Officer,
David W. Pritchard, will provide an overview of KaloBios and the company's three current clinical programs for its proprietary, patient-targeted monoclonal antibody therapeutics.
Wednesday July 10, 2013,
12:00 PM EDTWhere: The St. Regis Hotel,
New York City, NY
Webcast:To access the live and archived audio webcast of the JMP Securities presentation please log on through a link located in the Investors section of the KaloBios Pharmaceuticals, Inc. website under the Events & Presentations tab:
A replay of the webcast will be available one hour after the conclusion of the live event.
About KaloBiosKaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat severe medical conditions with a primary clinical focus on respiratory diseases and cancer. For more information on KaloBios Pharmaceuticals, Inc., please visit our web site at
Contact:Jeffrey H. CooperChief Financial OfficerKaloBios Pharmaceuticals, Inc.(650) 243-3146
email@example.comMedia Contact:Joan E. KureczkaKureczka/Martin Associates Tel: (415) 821-2413Mobile: (415) 690-0210
SOURCE KaloBios Pharmaceuticals, Inc.